(United States, Nevada, Las Vegas), DelveInsight’s “Complex regional pain syndromes- Pipeline Insight, 2023Pipeline Insight, 2023” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in the Complex regional pain syndromes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Complex Regional Pain Syndromes Pipeline Report
Over 3+ companies and 3+ pipeline drugs in Complex Regional Pain Syndromes are in various stages of development, and their anticipated acceptance in the Complex Regional Pain Syndromes market would significantly increase market revenue.
Leading Complex Regional Pain Syndromes companies developing novel drug candidates to improve the Complex Regional Pain Syndromes treatment landscape include TakedaTryp Therapeutics, Soin Therapeutics, and many others.
Promising Complex Regional Pain Syndromes pipeline therapies in various stages of development include TRP-8803, Soticlestat, and many others.
Complex Regional Pain Syndromes Overview
Complex regional pain syndrome (CRPS) is a term for a variety of clinical conditions characterized by chronic persistent pain and is subdivided into Type I and Type II CRPS. It is a condition that can develop after a limb trauma and appears mostly in one or more limbs. CRPS can be considered a regional post-traumatic neuropathic pain problem, and like other neuropathic pain disorders, symptoms are a disproportionate consequence of painful trauma or nerve lesion. Magnetic resonance imaging (MRI) can also be used to determine if tissue changes typical of CRPS and specialized magnetic resonance neurography can be used to evaluate for specific nerve involvement. CRPS has no cure. Treatment is most effective when started early and focuses on relieving symptoms, slowing the progression of the disease, and helping sufferers cope with the pain and lead as healthy lives as possible.
Complex Regional Pain Syndromes Pipeline Analysis: Drug Profile
Soticlestat is a novel, first-in-class therapy designed and developed as a selective CH24H inhibitor with the potential to reduce seizure susceptibility and improve seizure control1. In February 2022, the Minister of Health, Labour, and Welfare granted an orphan drug designation for soticlestat as a potential treatment for Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), both of which are developmental epileptic encephalopathies (DEEs), designated as intractable diseases in Japan. The Breakthrough Award from the Pharmaceutical Society of Japan recognizes Takeda’s research as contributing to the advancement of drug discovery research through the unique approaches taken to developing an innovative drug with a novel chemical structure. Takeda won this award for the first time in 9 years, marking its sixth win. Currently, the drug is in the Phase II stage of Clinical trial evaluation for the treatment of Complex Regional Pain Syndrome.
TRP-8803: Tryp Therapeutics
TRP-8803, a proprietary, psilocybin-based drug is manufactured exclusively for Tryp by Curia and Alcami and features a novel route of administration. Currently, the drug is in the Preclinical stage of development for the treatment of Complex Regional Pain Syndrome.
Discover more about the emerging Complex Regional Pain Syndromes drugs @ Complex Regional Pain Syndromes Treatment Drugs
Complex Regional Pain Syndromes Pipeline Therapies and Key Companies
TRP-8803: Tryp Therapeutics
And many others
DelveInsight’s Report covers around 33+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Complex Regional Pain Syndromes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.
Scope of the Complex Regional Pain Syndromes Pipeline Report
Key Complex Regional Pain Syndromes Companies: Takeda, Tryp Therapeutics, Soin Therapeutics, and many others
Key Complex Regional Pain Syndromes Pipeline Therapies: Soticlestat, TRP-8803, and many others.
Find out more about the Complex Regional Pain Syndromes treatment options in development @ Complex Regional Pain Syndromes Clinical Trials
Table of Contents
1. Complex Regional Pain Syndromes Introduction
2. Complex Regional Pain Syndromes Executive Summary
3. Complex Regional Pain Syndromes Overview
4. Complex Regional Pain Syndromes Pipeline Therapeutics
5. Complex Regional Pain Syndromes Late-Stage Products (Phase III)
6. Complex Regional Pain Syndromes Mid-Stage Products (Phase II)
7. Complex Regional Pain Syndromes Early Stage Products (Phase I/II)
8. Complex Regional Pain Syndromes Preclinical Stage Products
9. Complex Regional Pain Syndromes Discovery Stage Products
10. Complex Regional Pain Syndromes Therapeutic Assessment
11. Complex Regional Pain Syndromes Inactive Products
12. Complex Regional Pain Syndromes Collaborations Assessment- Licensing / Partnering / Funding
13. Complex Regional Pain Syndromes Unmet Needs
14. Complex Regional Pain Syndromes Market Drivers and Barriers
16. About DelveInsight
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States